Second Sight Medical Products EBITDA 2011-2026 | EYES

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Second Sight Medical Products

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-24.3 M	-26.6 M	-20.9 M	-13 M	-12.5 M	-30.2 M	-34.2 M	-28.2 M	-32.8 M	-19.7 M	-21 M	-17.7 M	-15.7 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-12.5 M	-34.2 M	-22.8 M

Quarterly EBITDA Second Sight Medical Products

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.62 M	-7.36 M	-6.46 M	-	-6.2 M	-5.58 M	-6.13 M	-	-	-	-6.49 M	-	-5.17 M	-4.06 M	-3.82 M	-1.29 M	-3.22 M	-2.26 M	-2.82 M	-1.27 M	-1.45 M	-2.99 M	-8.8 M	-8.13 M	-7.33 M	-8.24 M	-9.67 M	-8.88 M	-8.22 M	-7.77 M	-9.66 M	-7.43 M	-6.4 M	-6.64 M	-7.44 M	-10.4 M	-8.19 M	-8.3 M	-5.72 M	-5.48 M	-4.43 M	-4.79 M	-4.96 M	-5.56 M	-5.44 M	-5.42 M	-4.38 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-1.27 M	-10.4 M	-5.97 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Medical devices industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Acutus Medical AFIB	-11.5 M	-	-26.83 %	$ 2.62 M	USA
LivaNova PLC LIVN	228 M	$ 69.84	1.14 %	$ 3.79 B	Britain
Allied Healthcare Products AHPI	-815 K	-	3.58 %	$ 2.21 M	USA
GenMark Diagnostics, Inc. GNMK	-3.98 M	-	-	$ 1.77 B	USA
Cognyte Software Ltd. CGNT	8.53 M	$ 6.61	3.44 %	$ 475 M	Israel
Apollo Endosurgery APEN	-30.2 M	-	-	$ 475 M	USA
Alphatec Holdings ATEC	-4.64 M	$ 13.85	-0.57 %	$ 2.08 B	USA
Avinger AVGR	-16.3 M	-	-20.74 %	$ 369 K	USA
Obalon Therapeutics, Inc. OBLN	-9.8 M	-	-5.86 %	$ 30.6 M	USA
AxoGen AXGN	-1.19 M	$ 31.25	-3.85 %	$ 1.44 B	USA
Axonics Modulation Technologies AXNX	-53.2 M	-	-	$ 3.31 B	USA
Aziyo Biologics AZYO	-26.8 M	-	1.37 %	$ 20.5 M	USA
Apyx Medical Corporation APYX	-16.6 M	$ 3.46	-2.26 %	$ 120 M	USA
Conformis CFMS	-42.2 M	-	-	$ 16.4 M	USA
Bio-Rad Laboratories BIO	421 M	$ 269.55	0.25 %	$ 7.61 B	USA
BIOLASE BIOL	-15.1 M	-	-13.19 %	$ 166 K	USA
EDAP TMS S.A. EDAP	-18 M	$ 4.63	3.58 %	$ 173 M	France
Bruker Corporation BRKR	437 M	$ 39.92	0.38 %	$ 5.95 K	USA
BioSig Technologies BSGM	-12.7 M	-	37.08 %	$ 85.7 M	USA
Boston Scientific Corporation BSX	4.98 B	$ 74.02	-1.5 %	$ 110 B	USA
CryoLife, Inc. CRY	23.2 M	-	-4.14 %	$ 702 M	USA
ClearPoint Neuro CLPT	-18.8 M	$ 15.18	4.3 %	$ 410 M	USA
CONMED Corporation CNMD	120 M	$ 46.01	-0.07 %	$ 1.43 B	USA
Soliton, Inc. SOLY	-14.1 M	-	-1.42 %	$ 435 M	USA
Cardiovascular Systems CSII	-32.1 M	-	0.15 %	$ 844 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	88.4 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	-8.53 M	-	0.03 %	$ 1.58 B	Israel
Misonix, Inc. MSON	-15.9 M	-	-	$ 462 M	USA
Neovasc NVCN	-31.1 M	-	-	$ 111 M	Canada
InMode Ltd. INMD	86.1 M	$ 13.96	-0.14 %	$ 902 M	Israel
Cutera CUTR	-148 M	-	-10.19 %	$ 1.99 M	USA
Delcath Systems DCTH	-12.3 M	$ 10.16	2.11 %	$ 290 M	USA
Intersect ENT, Inc. XENT	-64.8 M	-	-	$ 955 M	USA
Dynatronics Corporation DYNT	-1.97 M	-	14.99 %	$ 929 K	USA
Eargo EAR	-106 M	-	-	$ 10.2 M	USA
Electromed ELMD	10.7 M	$ 23.53	1.64 %	$ 199 M	USA
Establishment Labs Holdings ESTA	-45.3 M	$ 77.39	-2.87 %	$ 2.18 B	Costa-rica
Nano-X Imaging Ltd. NNOX	-61 M	$ 2.46	1.23 %	$ 144 M	Israel
GBS GBS	-9.67 M	-	-0.57 %	$ 7.12 M	USA
FONAR Corporation FONR	9.84 M	$ 18.54	-0.16 %	$ 122 M	USA
Globus Medical GMED	757 M	$ 95.57	3.99 %	$ 12.9 B	USA
Profound Medical Corp. PROF	-30.3 M	$ 7.35	2.79 %	$ 180 M	Canada
Helius Medical Technologies HSDT	-12.4 M	$ 2.18	17.84 %	$ 1.33 M	USA
IRadimed Corporation IRMD	22.8 M	$ 100.38	1.3 %	$ 1.27 B	USA
Invacare Corporation IVC	-65 M	-	-	$ 24.7 M	USA
Integra LifeSciences Holdings Corporation IART	70.8 M	$ 11.54	0.09 %	$ 889 M	USA
Inogen INGN	-21.5 M	$ 6.07	3.94 %	$ 144 M	USA